1 Shotgun metagenomics reveals an enrichment of potentially cross-reactive bacterial epitopes in 2 ankylosing spondylitis patients, as well as the effects of TNFi therapy and the host's genotype upon 3 microbiome composition.

4

Jian Yin^{1*}, Peter R. Sternes^{2*}, Mingbang Wang³, Mark Morrison⁴, Jing Song¹, Ting Li¹, Ling Zhou¹, Xin Wu¹,
Fusheng He⁵, Jian Zhu⁶, Matthew A. Brown², Huji Xu^{1,6,7°}.

7

8 1. Department of Rheumatology and Immunology, Shanghai Changzheng Hospital, Second Military Medical University,

- 9 Shanghai, China.
- 10 2. Translational Genomics Group, Institute of Health and Biomedical Innovation, Queensland University of Technology,
- 11 Translational Research Institute, Brisbane, Australia.
- 12 3. Shanghai Key Laboratory of Birth Defects, Division of Neonatology, Children's Hospital of Fudan University, National Center
- 13 for Children's Health, Shanghai, 201102, China.
- 14 4. University of Queensland Diamantina Institute, Faculty of Medicine, Translational Research Institute, Brisbane, Australia.
- 15 5. Imunobio, Shenzhen, Guangdong, 518001, China.
- 16 6. Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua University, Beijing 100084, China.
- 17 7. Peking-Tsinghua Center for Life Sciences, Tsinghua University, Beijing 100084, China.
- 18
- 19 *These authors contributed equally to this manuscript.
- 20 ^o These authors contributed equally to this manuscript.
- 21

22 Corresponding Author:

- 23 Professor Matthew A. Brown,
- 24 Institute of Health and Biomedical Innovation,
- 25 Queensland University of Technology,
- 26 Translational Research Institute,
- 27 Princess Alexandra Hospital,
- 28 Woolloongabba, Brisbane,
- 29 Australia.
- 30 Telephone: +61 7 3443 7366
- 31 Fax : +61 7 3443 7102
- 32 matt.brown@qut.edu.au
- 33
- 34 Corresponding Author:
- 35 Professor Huji Xu
- 36 Beijing Tsinghua Changgeng Hospital
- 37 School of Clinical Medicine
- 38 Tsinghua University, Beijing 100084, China.
- 39 Phone: +86-10-6279 2998
- 40 Fax: +86-10-6278 9513
- 41 email: huji_xu@tsinghua.edu.cn

42 ABSTRACT

43 Diverse evidence including clinical, genetic and microbiome studies support a major role of the gut 44 microbiome in the common immune-mediated arthropathy, ankylosing spondylitis (AS). To further 45 investigate this we performed metagenomic analysis of a case-control cohort of 250 Han-Chinese 46 subjects. Previous reports of gut dysbiosis in AS were re-confirmed and several notable bacterial species 47 and functional categories were differentially abundant. TNF-inhibitor (TNFi) therapy at least partially restored the perturbed microbiome observed in untreated AS cases to that of healthy controls, including 48 49 several important bacterial species that have been previously associated with AS and other related 50 diseases. Enrichment of bacterial peptides homologous to HLA-B27-presented epitopes was observed in 51 the stools of AS patients, suggesting that either HLA-B27 fails to clear these or that they are involved in 52 driving HLA-B27-associated immune reactions. TNFi therapy of AS patients was also associated with a 53 reduction of potentially arthritogenic bacterial peptides, relative to untreated patients. An AS-associated 54 SNP in RUNX3 significantly influenced the microbiome in two independent cohorts, highlighting a host 55 genotype (other than HLA-B27) potentially influencing AS via the microbiome. These findings emphasise 56 the key role that the gut microbiome plays in driving the pathogenesis of AS.

57 **INTRODUCTION**

58 Ankylosing spondylitis (AS) is a chronic inflammatory disease affecting primarily the spine and pelvis, 59 causing pain and initially reversible stiffness, and ultimately leading to joint ankylosis due to ectopic 60 bone formation. In a subset of patients, peripheral joints and extra articular tissues including the eye, 61 gut and skin are also involved. Its prevalence in Asian and European descent populations ranges from 62 0.09% to 0.55% ^{1,2}, whereas the disease is rare in most of Africa, likely due to the low frequency of the main susceptibility gene, HLA-B27³. There is a significant unmet therapeutic need in AS, with limited 63 64 evidence that current therapies prevent spinal ankylosis, no oral treatments which suppress disease activity other than corticosteroids, and no treatments which have been demonstrated to induce 65 66 remission or prevent the disease.

67

68 AS has been shown in both twin and unrelated case/control studies to be highly heritable (twins >90% 69 heritability 4,5**,** unrelated case/control common variant heritability 69% 70 (http://www.nealelab.is/blog/2017/9/15/heritability-of-2000-traits-and-disorders-in-the-uk-biobank)). Over past decade, at least 116 susceptibility genes have been identified, contributing 29% of the overall 71 72 risk of the disease ⁶. There is substantial evidence suggesting that the interaction between host genetics 73 and gut microbiome is a key driver of the pathogenesis of AS. The high disease heritability indicates that 74 the environmental factors involved in the disease are likely to be ubiquitous. Reactive arthritis is a 75 spondyloarthritis sharing many clinical and genetic features with AS, and is known to be caused by 76 bacterial infections of the gut or urinary tract; a subset of reactive arthritis patients go on to develop AS. 77 About 60% AS patients suffered from subclinical bowel inflammation and 10% of them can be diagnosed as inflammatory bowel disease (IBD)⁷. There is considerable overlap in the overall heritability of AS and 78 IBD⁸, the two diseases are often co-familial⁹, and many shared genetic associations have been 79 80 identified ¹⁰. A bioinformatic study showed that AS susceptibility genes specifically enriched in gut cells

81 are also enriched in 'response to bacterium' GO term pathway, and that AS-associated genetic loci are 82 found disproportionately to lie within epigenetic marks of gene activity in gut tissue and cells ¹¹. Germ-free HLA-B27-transgenic rats and SKG mice are disease-free ^{12,13}. Studies using sequencing-83 84 based bacterial profiling of terminal ileal biopsies showed that AS patients have a distinct microbiome ¹⁴, 85 a finding that has subsequently been reproduced studying stool samples in AS patients and patients with spondyloarthritis (SpA), a broader clinical classification ^{15,16}. There has also been suggestive evidence 86 87 reported that the gut microbiome is associated with differences in AS disease activity ¹⁷. In addition, one 88 study compared SpA patients' stool samples before and three months after TNF-inhibitor (TNFi) 89 treatment onset ¹⁸. Although modest changes were found in microbiome alpha-diversity measures after 90 TNFi treatment, no changes in specific bacterial taxa were observed. This may have been related to power or sampling issues, noting that 15/18 patients studied met only the ASAS axial spondyloarthritis 91 92 classification criteria rather than having the more specific diagnosis, AS. In summation, the above 93 evidence supports the contention that AS status is influenced by interactions between the gut 94 microbiome and the host immune system.

95

96 To date, the mechanisms involved in the interaction between the host immune system and intestinal 97 microbes remain unclear. One hypothesis suggests that HLA-B27 presents specific peptides to CD8+ T 98 cells, leading to pathogenic adaptive immune responses (the 'arthritogenic peptide theory'). The gut 99 microbiota produce a huge variety and number of peptides, and as such, microbial peptides intrinsic to 100 dysbiosis may activate CD8+ T-cells In that context, Purcell and colleagues identified 7500 such peptides that bind the eight most common HLA-B27 subtypes ¹⁹. Here, we present our findings from a shotgun 101 102 metagenomics sequencing study undertaken with stool samples collected from in 250 Chinese 103 individuals, to investigate evidence of dysbiosis in AS, the effect of host genetic makeup and of TNFi

104 treatment on the gut microbiota, and to investigate evidence of immunity to HLA-B27 restricted

105 microbial peptides in AS cases.

106 MATERIALS AND METHODS

107 Subject recruitment

108 A total of 127 unrelated Han Chinese AS cases were recruited from the Department of Rheumatology 109 and Immunology of Shanghai Changzheng Hospital (Shanghai, China) from December 2014 to June 2017. 110 All cases met the 1984 modified New York criteria for AS²⁰. 123 healthy controls (blood donors on no 111 prescription medications) were recruited from Shanghai. All human studies have been approved by the Research Ethical Committee of Second Military Medical University, and all patients and controls gave 112 113 informed written consent for their participation in the studies. Clinical information was recorded for all patients, including demographic information (gender, age, smoking status and BMI), disease duration, 114 115 HLA-B27 carriage, sulfasalazine and TNFi treatment information, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)²¹ and Bath Ankylosing Spondylitis Functional Index (BASFI)²², and clinical 116 117 manifestations (inflammatory back pain, uveitis, axial arthritis, peripheral arthritis, ulcerative colitis, 118 Crohns disease, enthesitis, dactylitis and psoriasis). Dietary habits were assessed by a 52-question 119 questionnaire to exclude subjects with special dietary habits such as an entirely plant-based or meat-120 based diet. Where possible, Student's T test and Fisher's exact test were used to identify differences in 121 the metadata categories between cases and controls.

122

123 DNA microarray and subject genotyping

Samples were genotyped using the Infinium CoreExome-24v1-1 Chip (Illumina, San Diego, CA, USA) according to the manufacturer's recommendations. Bead intensity data were processed and normalised for each sample, and genotypes called within collection using GenomeStudio.

127

128 SNPs with call rate below 95% or with a Hardy-Weinberg equilibrium of $P < 10^{-6}$ in controls were 129 excluded. For the overlapping SNPs, pairwise missingness tests removed all SNPs with differential missingness (P < 10^{-7}). After merging data sets, SNPs with call rate below 98% and samples with call rate below 98% were removed. *HLA* alleles were imputed by SNP2HLA using the Pan-Asian reference panel ^{23,24} and SNPs were extracted by PLINK v.1.90²⁵.

133

134 Shotgun metagenome sequencing

Faecal samples were collected and stored at -80°C prior to DNA extraction. DNA was extracted using a StoolGen DNA kit (CWBiotech Co., Beijing, China). DNA concentrations were determined using a Qubit dsDNA BR assay kit (Thermo Fisher, Foster City, CA, USA). 200 – 500 bp insert size libraries were constructed using a TruSeq DNA Sample Preparation Kit (Illumina, San Diego, CA, USA) and an automated SPRI-Works system (Beckman Coulter, San Jose, CA, USA),

140

141 Quality Control (QC) of each library was carried out using an Agilent 2100 Bioanalyzer (Agilent 142 Technologies, Santa Clara, CA, USA), Qubit dsDNA BR assay kit (Thermo Fisher, Foster City, CA, USA) and 143 a KAPA qPCR MasterMix plus Primer Premix kit (Kapa Biosystems, Woburn, MA, USA) according to the 144 manufacturer's instructions. Libraries that passed QC (>3 ng/µL) were sequenced using an Illumina 145 HiSeq sequencer (Illumina, San Diego, CA, USA) with the paired-end 150-bp sequencing model based on 146 >5G raw data output per sample.

147

Manual inspection and QC of sequencing reads was conducted using FastQC v10.1 ²⁶. Paired-end reads were joined using PEAR v0.9.10 ²⁷ and adapters were trimmed using Trimmomatic v0.36 ²⁸. Contaminant sequences, such as those mapping to human or PhiX genomes, were filtered using Bowtie2 v2.3.4 ²⁹ and the remaining reads were counted and subsampled to an equal sequencing depth of 3,520,000 sequencing reads per sample using SeqTK v1.0 ³⁰. MetaPhIAn2 v2.6.0 ³¹ was used for taxonomic classification, PanPhIAn v1.2.2 ³² was used for strain-level profiling utilising pre-computed pan-genome references where possible, and HUMAnN2 v0.11.1 ³³ was used for functional mapping to KEGG
 Orthogroups (KO) and MetaCyc pathways and utilising a UniRef90 database.

156

For prediction of bacterial peptides homologous to previously reported HLA-B27-presented epitopes, bacterial-derived sequencing reads were BLASTXed against a local, BLAST-formatted ³⁴, version of the immune epitope database (IEDB) v3.0 (downloaded August 2016) ^{35,36}. BLAST best-hits with an E-value < 0.1 were retained, annotated according to a published study ³⁷ and then counted. The peptides annotated as HLA-B27-presented were compared between AS patients and healthy controls using Fisher's exact test.

163

164 Statistical Analysis

165 Abundance tables were arcsine square root transformed prior to analysis. Multidimensional data 166 visualisation was conducted using a sparse partial least squares discriminant analysis (sPLSDA) as 167 implemented in R as part of the MixOmics package v6.3.1³⁸, at the species level using Bray-Curtis 168 distance matrices. Receiver operating characteristic curve was calculated from sPLSDA using the 169 MixOmics package v6.3.1. Controlling for covariates (such as gender, BMI, age and smoking status) 170 where appropriate, multivariate association of the bacterial species composition with metadata of interest was conducted using a PERMANOVA test as part of vegan v2.4-5³⁹. The alpha diversity of 171 172 bacterial species was calculated using the rarefy function, as implemented in vegan v2.4-5. Univariate 173 association of bacterial species and functional pathways/groups were tested for significance using MaAsLin v0.0.5 ⁴⁰ and Wilcoxon rank-sum tests as implemented in R ⁴¹. Only results which were 174 significant in both tests were reported in the main text. For measurement of microbial epitope richness, 175 176 the Shannon, Simpson and Chao diversity indices were measured (vegan v2.4-5) and group differences were evaluated using Wilcoxon rank-sum tests. Genetic-relatedness dendrograms for strain-level results 177

178 from PanPhIAn were calculated using Jaccard distance matrices and hierarchical clustering as179 implemented in R v.3.5.2.

180

181 **RESULTS**

182 Gut dysbiosis in ankylosing spondylitis

183 We initially sought to confirm previous reports of dysbiosis in AS cases. The case and control cohorts 184 were divided into discovery and validation cohorts prior to analysis; the discovery cohort consisted of 97 185 AS cases and 93 healthy controls with age-matched demographics, and the remaining 60 subjects 186 comprised the validation cohort (30 AS cases and 30 healthy controls) (Supplementary Table 1). With 187 the exception of a difference in the mean age in the validation cohorts in which the controls were 188 younger on average than cases, no differences were observed between cases and controls in either the 189 discovery or validation cohorts. PERMANOVA and sPLSDA multivariate analysis revealed significant 190 differentiation between the microbial composition of AS cases and healthy controls for both the 191 discovery (P = 0.019) and validation (P = 0.0006) cohorts (Figure 1A), consistent with previous reports. 192 Receiver-operator curve analysis showed high discrimination between cases and controls using 193 microbiome data alone (AUC=0.87 in combined discovery and validation cohorts) (Supplementary Figure 194 1).

194

195

Seven bacterial species were identified to be differentially abundant (P < 0.05) (i.e. were 'indicator species') between AS cases and healthy controls, in both the discovery and validation cohorts (Figure 1B). *Clostridiales bacterium 1 7 47FAA, Clostridium bolteae* and *Clostridium hatheway* were found to be enriched in AS cases, whilst *Bifidobacterium adolescentis, Coprococcus comes, Lachnospiraceae bacterium 5 1 63FAA* and *Roseburia inulinivorans* were depleted. Several other differentially abundant species of interest were identified in either the discovery or validation cohort, notably *Prevotella copri*, 202 *Dialister invisus and Faecalibacterium prausnitzii.* A full list of differentially abundant taxa in either 203 cohort is available in Supplementary Table 2.

204

Six KEGG Orthogroups were also found to be differentially abundant (P < 0.05) in both cohorts (Figure 1C), however there were no MetaCyc metabolic pathways which were differentially abundant in both cohorts. The commonly-differentiated KEGG Orthogroups were EC 2.6.1.9: histidinol-phosphate transaminase, EC 2.7.4.1: polyphosphate kinase, EC 4.3.3.6: pyridoxal 5'-phosphate synthase, EC 1.15.1.1: superoxide proteinase, EC 3.4.21.53: ATP-dependent serine phosphatase, and EC 2.4.2.17: ATP phosphoribosyltransferase. Full lists of the differentially abundant KEGG Orthogroups and MetaCyc metabolic pathways are available in Supplementary Tables 3 and 4, respectively.

212

Linear regression was used to investigate the correlation between the indicator species and the commonly-differentiated KEGG Orthogroups. All indicator species, except for *Lachnospiraceae bacterium 5 1 63FAA*, were significantly associated (P < 0.05) with the KEGG Orthogroups, however the degree of variation explained by these species was typically low with R^2 values ranging from 0.0008 to 0.13 (0.043 on average) (Supplementary Table 5).

218

Strain-level profiling of the dysbiotic microbes identified in Figure 1B uncovered no discernible differences in strain composition between AS cases and healthy controls, with identical strains often being observed in both case and control subjects. (Supplementary Figure 2). This suggests that gut dysbiosis may primarily be a result of differential abundance at the species level and that functional or metabolic differences in the microbiome occur from common genetic elements amongst the strain population, as evidenced by KEGG Orthogroups being detectable in the majority of samples in Figure 1C.

226 Effect of TNFi therapy upon the microbiome

227 TNFi treatment is highly effective in AS, and it is feasible that at least some of its benefits occur through 228 effects on the gut microbiome. To test this hypothesis, the discovery and validation cohorts were 229 combined into the following categories: healthy controls (n = 123), AS cases treated with TNFi (either 230 etanercept or infliximab, n = 67), and AS cases who have not received TNFi treatment (n = 60). No 231 statistically significant effect of sulfasalazine treatment was observed (P=0.76, Supplementary Figure 3). 232 Multivariate comparison of TNFi untreated and treated cases revealed an effect of TNFi treatment upon 233 the overall composition of the microbiome (P = 0.022) (Figure 2A). Untreated cases were significantly 234 different to healthy controls (P = 0.0002), whereas treated cases were not significantly different to 235 healthy controls (P = 0.069) indicating that treatment has helped restore the perturbed composition of the microbiome. 236

237

238 To identify the key species modulated by the effects of TNFi therapy, species which were both (a) 239 perturbed in untreated AS cases relative to healthy controls, and (b) differently abundant in treated 240 cases compared to untreated cases, were first identified (Figure 2B and Supplementary Table 6). Six of 241 the eight identified species exhibited significant depletion in untreated AS cases, however TNFi 242 treatment appeared to restore the abundance of these species to levels indistinguishable from healthy 243 controls. These species were: Prevotella copri, Faecalibacterium prausnitzii, Bilophila unclassified, 244 Klebsiella pneumoniae, Ruminococcus bromii and Eubacterium biforme. The remaining two species 245 (Clostridium symbiosum and Eggerthella unclassified) were enriched in untreated AS and their 246 abundance was no longer different to healthy controls in treated cases. The findings in relation to 247 Prevotella copri and Klebsiella pneumoniae were of particular interest given their previous association 248 with rheumatoid arthritis (RA) and AS, respectively, as was the highly abundant (approximately 20% of 249 total bacterial DNA, on average) Faecalibacterium prausnitzii for its notable depletion in several autoimmune diseases ⁴². TNFi therapy appeared to partially normalise the dysbiotic bacterial species and KEGG Orthogroups observed in AS cases relative to healthy controls shown in Figures 1B and 1C, however no statistically significant differences between treated and untreated cases were observed, potentially due to sample size constraints (Supplementary Figure 4).

254

The above approach was also used to identify metabolic pathways modulated by TNFi therapy. 20 MetaCyc metabolic pathways were identified in total and the perturbed abundance observed in untreated AS cases was restored to healthy control levels in 17 of these. In broad terms, these pathways primarily related to amino acid biosynthesis (notably branched-chain and aromatic amino acid biosynthesis), carbohydrate metabolism (notably starch degradation), nucleotide biosynthesis, metabolite biosynthesis and cell structure. Specific details of the 20 differentially abundant MetaCyc pathways are available in Supplementary Table 7.

262

263 Linear regression was used to investigate the association of between the modulated species and 264 modulated pathways (Supplementary Table 8). Except for PWY-6545: Pyrimidine biosynthesis which was 265 not associated with any individual identified species, all the pathways were significantly associated with 266 at least two of the identified species. Similarly, all the species were significantly associated with multiple 267 pathways, however the abundances of *Bilophila unclassified* and *Klebsiella pneumonieae* were inversely 268 correlated with pathway abundance. An increase in *Klebsiella pneumonieae* was associated with a 269 decrease in the abundance of PWY-6737: starch degradation (P = 0.014; R² = -0.0426). The observed 270 decrease in the starch degradation pathway for untreated AS cases is primarily attributed to a depletion of Faecalibacterium prausnitzii (P = 2.38x10⁻²⁴; R² = 0.3123). Faecalibacterium prausnitzii also exhibited 271 272 strong associations with other metabolic pathways.

274 Strain-level profiling of the bacterial species outlined in Figure 2B also revealed no discernible 275 differences in strain composition between healthy controls, treated cases and untreated cases, 276 indicating the TNFi therapy affected the relative abundance of each species, not necessarily the 277 underlying strain composition (Supplementary Figure 5).

278

279 Effect of host genotype upon the microbiome

Genome-wide association studies (GWAS) have identified many genetic loci which are associated with AS. Emerging evidence indicates that alleles such as *HLA-B27* may influence the disease through its effect upon the gut microbiome ^{43,44}. To investigate whether additional loci may affect the gut microbiome and potentially influence disease, we performed PERMANOVA analysis upon loci known to be associated with AS.

285

286 Considering non-MHC loci, an association was noted for rs11249215, a SNP in the promoter of runt-287 related transcription factor 3 (RUNX3) gene known to be associated with AS ^{45,46}. This variant was associated with a shift in the microbiome of both AS cases and healthy controls (combined P = 0.0097). 288 289 Furthermore, sPLSDA revealed that the degree alteration appears dependent on whether the host 290 carried a heterozygous or homozygous genotype (Figure 3A), with the homozygous genotype resulting in 291 a more substantial shift. As further confirmation, we analysed a recently published 16S metabarcoding 292 dataset ⁴⁷ of 107 healthy control subjects which were sampled from six different body sites. This analysis 293 re-confirmed discrimination of the microbiomes based on genotype (PERMANOVA; P = 0.0001) (Figure 294 3B). The RUNX3 SNP had no observable effect upon the dysbiotic bacterial species and KEGG 295 Orthogroups outlined in Figures 1B and 1C, however its effects upon species richness and community 296 composition (Figure 3A) suggest that further research is required to confirm a role in AS pathogenesis 297 via effects upon the microbiome. The effect of HLA-B27 upon the microbiome of the current cohort was

unable to be investigated due to high prevalence of this genotype in AS cases and low prevalence in
healthy controls, thus the effect of *HLA-B27* was unable to be discerned from the effect of AS itself.

300

To highlight the key bacterial species affected by rs11249215, species associated with the heterozygous (AG) and homozygous (GG) genotypes, or solely the homozygous (GG) genotype were identified (Figure 3C). Several bacterial species showed differential abundance for the AG genotype, but not the GG genotype, potentially due to sample size constraints (the GG genotype was present in 37 of the 188 genotyped subjects), and thus were excluded from further analysis. Four key species identified as depleted in the AG/GG genotypes were: *Lachnospiraceae bacterium 1 1 57FAA*, *Eubacterium ventriosum*, *Citrobacter freundii* and *Citrobacter unclassified* (Supplementary Table 9).

308

Six MetaCyc metabolic pathways were found to be differentially abundant when comparing *RUNX3* rs11249215 genotypes (Figure 3D). Similar to the differences found for TNFi therapy, the differential pathways were primarily associated with amino acid and nucleotide biosynthesis, however notable differences in polyamine biosynthesis and pyruvate fermentation (to acetate and lactate) were also observed. Of interest is the polyamine biosynthesis pathway for the role of polyamines in enhancing the integrity of the intestinal epithelial cell barrier, and the adenosine biosynthesis pathway for the antiinflammatory and immunosuppressant effect of adenosine (Supplementary Table 10) ^{48,49}.

316

Linear regression of these species with the metabolic pathways revealed relatively marginal associations, with the two *Citrobacter* species exhibiting no association with any metabolic pathway (Supplementary Table 11). 16S rRNA gene metabarcoding analysis of the predominately Caucasian cohort sampled from various body sites (Figure 3B) revealed a different set of taxa and metabolic pathways potentially influenced by the *RUNX3* SNP (Supplementary Tables 12 and 13). The minimal

overlap with the current shotgun metagenomic study is potentially indicative of the differences between
 the metagenomic approaches and/or differences in studied cohorts (i.e. geographic location, diet,
 ethnicity...etc).

325

326 Similar to the strain-level results for AS status and TNFi therapy, no observable bias in the underlying 327 strain population was observed, indicating that RUNX3 variants likely affect the relative abundance of species, not necessarily strain composition (Supplementary Figure 6^{47,50}). Comparatively fewer species 328 329 were associated with the RUNX3 SNP in comparison to the number of species associated with AS status and TNFi treatment. Consistent with recent publications which have investigated the effect of the host's 330 genotype upon the abundance of specific taxa ^{47,50}, these data provide supporting evidence that the 331 332 underlying host's genetics may have a generalised effect upon the microbiome, with a subtle effect on a 333 higher number of taxa as opposed to a marked effect on a select few.

334

335 Bacterial-derived HLA-B27 epitopes in AS cases and healthy controls

The main physiological function of HLA-B27 is to present peptides to CD8 lymphocytes, thereby driving cell mediated immune reactions. Differences in the presence of HLA-B27-positive epitopes in the gut microbiome in cases compared to controls, and in HLA-B27 carriers compared with HLA-B27-negative subjects, would be consistent with effects of HLA-B27 to 'shape' the gut microbiome, and the significance of this in regards disease pathogenesis.

341

To investigate the abundance of bacterial peptides homologous to HLA-B27 epitopes in AS cases and healthy controls, translated nucleotide searches were performed against IEBD v3.0, annotated according to a published study ³⁷ and counted. Significant enrichment of these peptide sequences was observed in AS cases, with 24 of these enriched in both the discovery and validation cohorts (Table 1). AS cases not

346	only exhibited enrichment of these peptides but the overall diversity of peptides was increased, with
347	Shannon, Inverse Simpson and Chao diversity indices revealing significant differences between AS cases
348	and healthy controls (Figure 4A).
349	
350	TNFi treatment effects were also investigated. The overall abundance and diversity of bacterial peptides
351	homologous to HLA-B27-presented epitopes was significantly different between the different treatment
352	categories (Figure 4B). Untreated AS cases exhibited increased abundance and diversity of peptides. For
353	patients who underwent TNFi therapy, a reduction in these potentially arthritogenic peptides was
354	observed relative to untreated cases, however their levels remained marginally higher than healthy

355 controls.

356 **DISCUSSION**

357 Gut dysbiosis in ankylosing spondylitis

358 This study re-confirmed the occurrence of bacterial gut dysbiosis in AS cases and identified seven 359 bacterial species which were commonly differentiated between cases and controls in both the discovery 360 and validation cohorts (Figure 1B). Two of these species, Bifidobacterium adolescentis and Coprococcus comes, have been noted for their depletion in Crohn's Disease ⁵¹ and were also observed to be depleted 361 362 in AS cases in this study. An additional two species previously reported to be associated with AS, Prevotella copri and Dialister invisus, were found to be differentially abundant in either the discovery or 363 364 validation cohorts (Supplementary Table 2). In the case of Prevotella copri, previous studies have demonstrated enrichment in new onset RA cases yet depletion in chronic RA cases ⁵². Consistent with 365 these findings, our study found that Prevotella copri was depleted in AS cases within the non-age-366 367 matched cohort, for which the demographics were heavily skewed towards older AS patients with long-368 standing disease (Supplementary Table 1). Previous studies in AS have shown increases in Prevotellaceae ¹⁴, or specifically with this species ¹⁵. As discussed below, *Prevotella copri* carriage normalised with TNFi 369 370 treatment. Further studies will be required to determine if Prevotella copri carriage changes with 371 disease duration, as has been reported in RA.

372

Carriage of *Dialister* species has been previously associated with disease activity in spondylarthrosis patients ¹⁷, but the carriage of *Dialister invisus* has been reported to be decreased in inflammatory bowel disease (IBD) ^{53,54}. Whilst we found enrichment of *Dialister invisus* in AS cases in the discovery cohort, this was not confirmed in the validation cohort, nor has it been reported in other AS studies. Its pathogenic significance is therefore uncertain.

379 Of particularly interest, the notable 'peace keeping' microbe Faecalibacterium prausnitzii was also found 380 to be depleted in AS cases in the validation cohort. This bacterium has also been consistently shown to 381 be depleted in IBD ⁵⁴⁻⁵⁹, and has been previously shown to be depleted in the disease enthesitis-related 382 arthritis, a paediatric disease-classification which includes children with ankylosing spondylitis ⁶⁰. 383 Faecalibacterium prausnitzii is known to produce butyrate and other metabolites and peptides that have 384 diverse anti-inflammatory effects including promoting T-regulatory cell differentiation ⁶¹, influences on Th17 lymphocyte activation, and promotion of gut mucosal barrier function ^{59,62,63}. As discussed below, 385 386 TNFi treatment also led to normalisation of *Faecalibacterium prausnitzii* carriage. These findings suggest 387 that Faecalibacterium prausnitzii plays a key anti-inflammatory role in AS, as it does in IBD.

388

389 The power of metagenome sequencing is to augment the widely observed phenomena collectively 390 referred to as "dysbiosis" beyond taxonomy-based assessment of microbiome, and provide a more 391 highly resolved and functional characterisation of the microbiome. Here, variation in several KEGG 392 Orthogroups remained consistent between the discovery and validation cohorts (Figure 1C). Additionally, differential abundance of some MetaCyc metabolic pathways was also observed 393 394 (Supplementary Table 4), but these differences were not consistent between discovery and validation 395 cohorts; potentially highlighting the confounding influence of the host's age upon the metabolic 396 composition of the gut microbiome.

397

Interestingly, genes encoding pyridoxal 5'-phosphate synthase, an important enzyme for the biosynthesis of vitamin B6, were less abundant amongst the microbiome of AS cases compared to healthy controls in both cohorts. Vitamin B6 plays a role in the maintenance of vitamin homeostasis in colonocytes ^{64,65}. It has been found to modulate colonic inflammation and several studies have investigated the role of vitamin B6 for the treatment of inflammation in RA patients ⁶⁶⁻⁷¹. Evidence from

403 case-control studies show that RA patients have low vitamin B6 status compared to healthy controls, 404 however intervention studies have yielded inconsistent findings, possibly due to the dose of the 405 administered vitamin B6. The reduced potential for the microbiome of AS patients to produce pyridoxal 406 5'-phosphate synthase, and thus vitamin B6, may warrant further investigation into intervention 407 strategies to mitigate inflammation in AS patients.

408

409 Effect of TNFi therapy upon the microbiome

Previous study of RA patients before and after synthetic disease-modifying anti-rheumatic drug treatment revealed moderate differences in the gut microbiota composition, with the perturbed microbial composition being party restored following treatment ⁷². Similarly, analysis of spondylarthrosis patients before and after TNFi therapy also revealed modest differences in microbial composition yet no specific taxon was found to be modulated, likely due to sample size ⁷³. Utilising a larger sample size, we confirmed that TNFi therapy was correlated with a restoration of the perturbed microbial composition, and additionally identified several notable bacterial species modulated by treatment.

417

418 We observed that TNFi therapy restored the depletion of Faecalibacterium prausnitzii in AS cases. 419 Restoration of Faecalibacterium prausnitzii abundance was also correlated with the restored abundance of aromatic and branched-chain amino acid biosynthesis pathways. A recent ulcerative colitis study ⁵⁵ 420 421 revealed reduced dysbiosis and increased Faecalibacterium prausnitzii abundance in responders 422 compared with non-responders following TNFi therapy. Furthermore, recovery of Faecalibacterium 423 prausnitzii in patients with ulcerative colitis after relapse was associated with maintenance of remission 424 ⁷⁴. Another study demonstrated that treatment of infliximab completely restored *Faecalibacterium* prausnitzii concentrations from zero to 1.4×10^{10} bacteria/mL within few days ⁵². 425

426

427 Another important microbe, Prevotella copri, was observed to be enriched to levels closely matched to 428 that of healthy controls following TNFi treatment. Abundance of Prevotella copri has previously been 429 shown to be enriched in untreated new onset RA patients yet depleted in chronic RA cases, patients with psoriatic arthritis and healthy controls ⁵². Colonisation of SKG mice with *Prevotella copri*-dominated 430 431 microbiota from RA patients exhibited increased number of Th17 cells in the large intestine ⁷⁵. HLA-DR-432 presented peptides (T cell epitopes) from Prevotella copri were recently found to stimulate Th1 responses in 42% of new onset RA cases, with subgroups of RA patients demonstrating differential IgG 433 434 or IgA immune reactivity, providing evidence that Prevotella copri is immune-relevant in RA pathogenesis ⁷⁶. Additionally, the presence of the HLA-DRB1 risk allele, which influences disease 435 severity, in RA patients was found to be inversely correlated with *Prevotella copri* abundance ^{52,77-79}. A 436 437 recent study of Chinese AS patients revealed enrichment of Prevotella copri, as well as Prevotella melaninogenica and Prevotella sp. C561^{15,80}. Contrasting these results, in the current study we observed 438 439 depletion of Prevotella copri in untreated AS cases, which was restored to the healthy control levels in 440 TNFi-treated patients. These seemingly conflicting reports of Prevotella copri abundance may be 441 explained by the large degree of intraspecific genetic diversity of *Prevotella copri* strains, with strain 442 variation adding an additional layer of complexity for predicting the function of Prevotella copri in the gut. The Prevotella genus also contains members that may be beneficial, and which do not function as 443 pathobionts ⁷⁷⁻⁷⁹, with observed enrichment in healthy individuals. Taken together, our results which 444 445 demonstrate a modulation of *Prevotella copri* abundance in TNFi-treated cases is a noteworthy 446 observation, however without a stronger grasp of the strain-level genome variation within this taxon 447 and their prevalence across our cohort, attempts to therapeutically modulate and predict the effects of Prevotella copri remains a significant challenge⁸¹. 448

450 Klebsiella pneumoniae has also been suggested to play a significant role in AS pathogenesis ⁸², although this remains controversial⁸³. *Klebsiella pneumoniae* notably produces pullulanase, a starch-debranching 451 enzyme which enables the degradation of starch into simple sugars ⁸⁴. The apparent arthritogenic 452 453 effects of dietary starch in AS are based on the concept that the growth of *Klebsiella sp.* are favoured by 454 these diets and drive AS pathogenesis ^{85,86}. Consequently, low starch diets have been promoted and are frequently followed by patients ⁸⁶, although there is no published evidence to date as to their efficacy in 455 456 positively affecting AS disease course. Here, we actually observed a depletion of this microbe in 457 untreated cases relative to healthy controls, whereas TNFi-treated cases showed a restoration of this 458 bacterium. Furthermore, our metagenome sequencing data showed an inverse correlation between 459 Klebsiella pneumoniae relative abundance and the overall starch degradation metabolic pathway (P =0.014; $R^2 = -0.043$) (Supplementary Table 5). This pathway not only includes the pullulanase-mediated 460 461 starch de-branching reaction, but also further downstream reactions including the transport and 462 catabolism of maltodextrins. These findings do not support an association between Klebsiella 463 pneumoniae and AS pathophysiology, although the role of dietary and/or resistant starches on the gut 464 microbiota and AS warrants further investigation.

465

MetaCyc pathway analysis revealed depletion of the aromatic and branched-chain amino acid 466 467 biosynthesis pathways in untreated AS cases, which are responsible for production of four of the nine 468 essential amino acids in humans (leucine, isoleucine, valine and phenylalanine) (Supplementary Table 7). 469 Vitamin B6 is an essential co-factor for branched-chain amino acid transaminase, the last step of 470 branched-chain amino acid synthesis, and was found to be depleted in RA cases, as previously mentioned. Therefore, in the current study we not only observed a depletion of genes encoding the 471 472 branched-chain amino acid biosynthesis pathway, but also for the enzyme which synthesises an 473 important co-factor in the process.

474

475 Enrichment of potentially arthritogenic bacterial peptides

476 Pathogenic bacteria have long been hypothesised as an immunological triggers of AS pathogenesis. In 477 the current study, patients with AS not only demonstrated an enrichment of bacterial peptides matching 478 HLA-B27 epitopes (Table 1), but the diversity of these peptides was greater overall (Figure 4A). These 479 data provide supporting evidence for the molecular mimicry hypothesis for which bacterial-derived 480 peptides may stimulate AS via cross-activation of autoreactive T- or B- cells, thus leading to 481 autoimmunity. This hypothesis does not however explain the increase in HLA-B27 epitopes amongst AS cases, which could be explained by effects of non-HLA genetic factors, or AS-associated environmental 482 483 factors. An alternate hypothesis is that their excess carriage is caused by a deficiency in the ability of 484 HLA-B27 to effectively control their presence, consistent with evidence of increased bacterial migration across the gut mucosa in AS⁸⁷. Interestingly, the modulation of the gut microbiome caused by TNFi 485 486 treatment restored the elevated abundance and diversity of peptides observed in untreated cases to 487 levels which were more closely matched to healthy controls (Figure 4B). Further research will be 488 required to resolve these alternate hypotheses.

489

490 Effect of host genotype upon the microbiome

Very recently, it was demonstrated that HLA-B27 is associated with a significant shift in the microbiome in healthy individuals ⁴⁷. Furthermore, in mouse models, MHC polymorphisms were demonstrated to contribute to an individual's microbial composition, thus influencing health ⁸⁸. Our investigation revealed an additional AS-associated SNP, rs11249215 in *RUNX3* ^{45,46}, which was also correlated with a significant shift in bacterial composition (Figure 3A). This result was replicated in a confirmatory dataset of healthy Caucasian individuals (Figure 3B). In addition to potential roles in autoimmune diseases, variants in *RUNX3* have been associated with the intestinal inflammatory disorder celiac disease ⁸⁹, and

RUNX3-knockout mice spontaneously develop IBD ⁹⁰. It is therefore tempting to hypothesise that the 498 499 role of *RUNX3* in disease pathogenesis is, at least in part, caused by perturbation of the gut microbiome. 500 Interestingly, subjects homozygous for rs11249215 exhibited a significant decrease in the abundance of 501 the polyamine biosynthesis superpathway (Figure 3D). The intestinal tract contains high levels of 502 polyamines which are critical for cell growth and can stimulate the production of junction proteins 503 which are crucial for regulating paracellular permeability and reinforcing epithelial barrier function. 504 Shifts in host and microbial polyamine metabolism may also alter the cytokine environment and induce cellular processes in both acute and chronic inflammatory settings ⁴⁹. A potential relationship between 505 506 RUNX3, microbial composition, intestinal polyamine levels and epithelial permeability and/or the 507 cytokine environment warrants further investigation.

509 CONCLUSION

510 In this study we confirm that AS is characterised by gut dysbiosis and identify key indicator species, 511 several of which are shared with IBD. This dysbiosis is associated with functional differences in the 512 microbiome involving known inflammation-related pathways. We demonstrate that treatment with 513 TNFi, which is highly effective in suppressing the clinical manifestations of AS, normalises the gut 514 microbiome, and its functional properties, in AS cases. We further demonstrate that the AS gut 515 microbiome is enriched for bacterial peptides that have previously been shown to be presented by HLA-516 B27, and that this enrichment is also normalised by TNFi treatment. The impact of the host's genotype 517 upon microbiome composition was also highlighted, with an AS- and IBD-associated SNP in RUNX3 518 correlating with a shift in microbiome composition. These findings are consistent with disease models in 519 which AS pathogenesis is driven by interactions between a genetically primed host immune system, and 520 the gut microbiome, and point to potential therapeutic and/or preventative approaches for the disease.

521

522 AUTHOR CONTRIBUTIONS

523 Study design was performed by HX, JY and MAB. Subject recruitment and sample collection was 524 performed by JY, JS, TL, LZ, XW and JZ. Metagenomic analysis was performed by PRS, and bacterial 525 epitope studies by JY, FH and MW. The manuscript was prepared by PRS, MM, MAB and HX.

526

527 ACKNOWLEDGEMENTS

528 HX is supported by National Science Foundation of China (Grant 81302578) and China Ministry of 529 Science and technology (973 Program of China 2014CB541800). MAB is funded by a National Health and 530 Medical Research Council Senior Principal Research Fellowship (APP1024879).

532 **REFERENCES**

- 5331.Wang, R. & Ward, M.M. Epidemiology of axial spondyloarthritis: an update. Current opinion in534rheumatology **30**, 137-143 (2018).
- 535 2. Braun, J., *et al.* Prevalence of spondylarthropathies in HLA-B27 positive and negative blood 536 donors. *Arthritis Rheum* **41**, 58-67 (1998).
- 5373.Brown, M.A., et al. Ankylosing spondylitis in West Africans--evidence for a non-HLA-B27538protective effect. Ann Rheum Dis 56, 68-70 (1997).
- 539 4. Pedersen, O.B., *et al.* Ankylosing spondylitis in Danish and Norwegian twins: occurrence and the
 540 relative importance of genetic vs. environmental effectors in disease causation. *Scand J*541 *Rheumatol* 37, 120-126 (2008).
- 542 5. Brown, M.A., *et al.* Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and 543 the environment. *Arthritis Rheum* **40**, 1823-1828 (1997).
- Ranganathan, V., Gracey, E., Brown, M.A., Inman, R.D. & Haroon, N. Pathogenesis of ankylosing
 spondylitis recent advances and future directions. *Nature reviews. Rheumatology* 13, 359-367
 (2017).
- 547 7. Mielants, H., et al. The evolution of spondyloarthropathies in relation to gut histology. II.
 548 Histological aspects. J Rheumatol 22, 2273-2278 (1995).
- 5498.Ellinghaus, D., et al. Analysis of five chronic inflammatory diseases identifies 27 new associations550and highlights disease-specific patterns at shared loci. Nature genetics 48, 510-518 (2016).
- 551 9. Thjodleifsson, B., Geirsson, A.J., Bjornsson, S. & Bjarnason, I. A common genetic background for
 552 inflammatory bowel disease and ankylosing spondylitis: a genealogic study in Iceland. Arthritis
 553 *Rheum* 56, 2633-2639 (2007).
- Parkes, M., Cortes, A., van Heel, D.A. & Brown, M.A. Genetic insights into common pathways
 and complex relationships among immune-mediated diseases. *Nature reviews. Genetics* 14, 661673 (2013).
- Li, Z., et al. Epigenetic and gene expression analysis of ankylosing spondylitis-associated loci implicate immune cells and the gut in the disease pathogenesis. *Genes and immunity* 18, 135-143 (2017).
- 56012.Taurog, J.D., et al. The germfree state prevents development of gut and joint inflammatory561disease in HLA-B27 transgenic rats. The Journal of experimental medicine **180**, 2359-2364 (1994).
- Rehaume, L.M., *et al.* ZAP-70 genotype disrupts the relationship between microbiota and host,
 leading to spondyloarthritis and ileitis in SKG mice. *Arthritis & rheumatology* 66, 2780-2792
 (2014).
- 56514.Costello, M.E., et al. Brief Report: Intestinal Dysbiosis in Ankylosing Spondylitis. Arthritis &566rheumatology 67, 686-691 (2015).
- 56715.Wen, C., et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in
ankylosing spondylitis. Genome biology 18, 142 (2017).
- 56916.Breban, M., et al. Faecal microbiota study reveals specific dysbiosis in spondyloarthritis. Ann570Rheum Dis **76**, 1614-1622 (2017).
- 57117.Tito, R.Y., et al. Brief Report: Dialister as a Microbial Marker of Disease Activity in572Spondyloarthritis. Arthritis & rheumatology 69, 114-121 (2017).
- 57318.Bazin, T., et al.MicrobiotaCompositionMayPredictAnti-TnfAlphaResponsein574Spondyloarthritis Patients: an Exploratory Study. Scientific reports **8**, 5446 (2018).
- 575 19. Schittenhelm, R.B., Sian, T.C., Wilmann, P.G., Dudek, N.L. & Purcell, A.W. Revisiting the
 576 arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of
 577 HLA-B27 allotypes. *Arthritis & rheumatology* 67, 702-713 (2015).

- 578 20. Linden, S.V.D., Valkenburg, H.A. & Cats, A. Evaluation of diagnostic criteria for ankylosing 579 spondylitis. *Arthritis & rheumatology* **27**, 361-368 (1984).
- 58021.Garrett, S., et al. A new approach to defining disease status in ankylosing spondylitis: the Bath581Ankylosing Spondylitis Disease Activity Index. J Rheumatol **21**, 2286-2291 (1994).
- 582 22. Calin, A., et al. A new approach to defining functional ability in ankylosing spondylitis: the
 583 development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21, 2281-2285
 584 (1994).
- 58523.Das, S., et al. Next-generation genotype imputation service and methods. Nature genetics 48,5861284 (2016).
- 587 24. Jia, X., *et al.* Imputing amino acid polymorphisms in human leukocyte antigens. *PloS one* **8**, e64683 (2013).
- 25. Rentería, M.E., Cortes, A. & Medland, S.E. Using PLINK for genome-wide association studies
 (GWAS) and data analysis. in *Genome-Wide Association Studies and Genomic Prediction* 193-213
 (Springer, 2013).
- 592 26. And rews, S. FastQC: a quality control tool for high throughput sequence data. (2010).
- 59327.Zhang, J., Kobert, K., Flouri, T. & Stamatakis, A. PEAR: a fast and accurate Illumina Paired-End594reAd mergeR. *Bioinformatics* **30**, 614-620 (2013).
- 59528.Bolger, A.M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence596data. *Bioinformatics* **30**, 2114-2120 (2014).
- 59729.Langmead, B. & Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nature methods 9, 357598(2012).
- 599 30. Li, H. seqtk Toolkit for processing sequences in FASTA/Q formats. (GitHub, 2012).
- 60031.Truong, D.T., et al. MetaPhlAn2 for enhanced metagenomic taxonomic profiling. Nature601methods 12, 902 (2015).
- 60232.Scholz, M., et al. Strain-level microbial epidemiology and population genomics from shotgun603metagenomics. Nature methods 13, 435 (2016).
- 60433.Abubucker, S., et al. Metabolic reconstruction for metagenomic data and its application to the605human microbiome. PLoS computational biology 8, e1002358 (2012).
- 60634.Altschul, S.F., Gish, W., Miller, W., Myers, E.W. & Lipman, D.J. Basic local alignment search tool.607Journal of molecular biology **215**, 403-410 (1990).
- 60835.Vita, R., et al. The immune epitope database (IEDB) 3.0. Nucleic acids research 43, D405-D412609(2014).
- 61036.Kim, Y., et al. Immune epitope database analysis resource. Nucleic acids research 40, W525-611W530 (2012).
- Schittenhelm, R.B., Sian, T.C., Wilmann, P.G., Dudek, N.L. & Purcell, A.W. Revisiting the
 arthritogenic peptide theory: quantitative not qualitative changes in the peptide repertoire of
 HLA–B27 allotypes. *Arthritis & rheumatology* 67, 702-713 (2015).
- 61538.Lê Cao, K.-A., et al. MixMC: a multivariate statistical framework to gain insight into microbial616communities. PloS one 11, e0160169 (2016).
- 617 39. Dixon, P. VEGAN, a package of R functions for community ecology. *Journal of Vegetation Science*618 14, 927-930 (2003).
- Morgan, X.C., *et al.* Dysfunction of the intestinal microbiome in inflammatory bowel disease and
 treatment. *Genome biology* 13, R79 (2012).
- 41. Ihaka, R. & Gentleman, R. R: a language for data analysis and graphics. *Journal of computational and graphical statistics* 5, 299-314 (1996).
- 42. Forbes, J.D., Van Domselaar, G. & Bernstein, C.N. The gut microbiota in immune-mediated inflammatory diseases. *Frontiers in microbiology* **7**, 1081 (2016).

43. Kenna, T.J. & Brown, M.A. Immunopathogenesis of ankylosing spondylitis. *Int J Clin Rheumatol* 8, 265-274 (2013).

627 44. Rosenbaum, J.T., *et al.* Does the microbiome play a causal role in spondyloarthritis? *Clinical* 628 *rheumatology* **33**, 763-767 (2014).

Evans, D.M., et al. Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates
peptide handling in the mechanism for HLA-B27 in disease susceptibility. *Nature genetics* 43, 761 (2011).

46. International Genetics of Ankylosing Spondylitis, C., et al. Identification of multiple risk variants
for ankylosing spondylitis through high-density genotyping of immune-related loci. Nature
genetics 45, 730-738 (2013).

635 47. Asquith, M., *et al.* HLA alleles associated with risk of ankylosing spondylitis and rheumatoid 636 arthritis influence the gut microbiome. *bioRxiv*, 517813 (2019).

48. Varani, K., et al. The role of adenosine receptors in rheumatoid arthritis. Autoimmunity reviews
538 10, 61-64 (2010).

49. Rooks, M.G. & Garrett, W.S. Gut microbiota, metabolites and host immunity. *Nature Reviews Immunology* 16, 341 (2016).

64150.Rothschild, D., et al. Environment dominates over host genetics in shaping human gut642microbiota. Nature 555, 210 (2018).

643 51. Gevers, D., *et al.* The treatment-naive microbiome in new-onset Crohn's disease. *Cell host & microbe* **15**, 382-392 (2014).

52. Scher, J.U., *et al.* Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. *elife* **2**(2013).

53. Joossens, M., *et al.* Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. *Gut* **60**, 631-637 (2011).

64954.Schirmer, M., et al. Dynamics of metatranscription in the inflammatory bowel disease gut650microbiome. Nat Microbiol **3**, 337-346 (2018).

55. Magnusson, M.K., *et al.* Anti-TNF therapy response in patients with ulcerative colitis is
associated with colonic antimicrobial peptide expression and microbiota composition. *Journal of Crohn's and Colitis* 10, 943-952 (2016).

65456.De Preter, V., et al. Faecal metabolite profiling identifies medium-chain fatty acids as655discriminating compounds in IBD. Gut, gutjnl-2013-306423 (2014).

57. Le Gall, G., *et al.* Metabolomics of fecal extracts detects altered metabolic activity of gut
microbiota in ulcerative colitis and irritable bowel syndrome. *Journal of proteome research* 10,
4208-4218 (2011).

65958.Marchesi, J.R., et al. Rapid and noninvasive metabonomic characterization of inflammatory660bowel disease. Journal of proteome research 6, 546-551 (2007).

66159.Machiels, K., et al. A decrease of the butyrate-producing species Roseburia hominis and662Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275-6631283 (2014).

66460.Stoll, M.L., et al. Altered microbiota associated with abnormal humoral immune responses to665commensal organisms in enthesitis-related arthritis. Arthritis Res Ther 16, 486 (2014).

666 61. Arpaia, N., *et al.* Metabolites produced by commensal bacteria promote peripheral regulatory T667 cell generation. *Nature* 504, 451-455 (2013).

668 62. Sokol, H., et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium
669 identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105,
670 16731-16736 (2008).

671 63. Neis, E., Dejong, C. & Rensen, S.J.N. The role of microbial amino acid metabolism in host 672 metabolism. **7**, 2930-2946 (2015). 673 64. Rucker, R.B., Suttie, J.W. & McCormick, D.B. Handbook of vitamins, (CRC Press, 2001).

- 674 65. Magnúsdóttir, S., Ravcheev, D., de Crécy-Lagard, V. & Thiele, I. Systematic genome assessment
 675 of B-vitamin biosynthesis suggests co-operation among gut microbes. *Frontiers in genetics* 6,
 676 148 (2015).
- 66. Woolf, K. & Manore, M.M. Elevated plasma homocysteine and low vitamin B-6 status in nonsupplementing older women with rheumatoid arthritis. *Journal of the American Dietetic Association* 108, 443-453 (2008).
- 680 67. Schumacher, H., Bernhart, F. & György, P. Vitamin B6 levels in rheumatoid arthritis: effect of 681 treatment. *The American journal of clinical nutrition* **28**, 1200-1203 (1975).
- 682 68. Chiang, E.-P.I., Bagley, P.J., Selhub, J., Nadeau, M. & Roubenoff, R. Abnormal vitamin B6 status is
 683 associated with severity of symptoms in patients with rheumatoid arthritis. *The American*684 *journal of medicine* **114**, 283-287 (2003).
- 685 69. Chiang, E.-P.I., Selhub, J., Bagley, P.J., Dallal, G. & Roubenoff, R. Pyridoxine supplementation
 686 corrects vitamin B6 deficiency but does not improve inflammation in patients with rheumatoid
 687 arthritis. Arthritis research & therapy 7, R1404 (2005).
- 68870.O'connor, Á. An overview of the role of diet in the treatment of rheumatoid arthritis. Nutrition689bulletin **39**, 74-88 (2014).
- 69071.Selhub, J., et al. Dietary vitamin B6 intake modulates colonic inflammation in the IL10-/- model691of inflammatory bowel disease. The Journal of nutritional biochemistry 24, 2138-2143 (2013).
- 72. Zhang, X., *et al.* The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly
 normalized after treatment. *Nature medicine* **21**, 895 (2015).
- 69473.Bazin, T., et al.MicrobiotaCompositionMayPredictAnti-TnfAlphaResponsein695Spondyloarthritis Patients: an Exploratory Study. Scientific reports **8**, 5446 (2018).
- 696 74. Varela, E., et al. Colonisation by Faecalibacterium prausnitzii and maintenance of clinical
 697 remission in patients with ulcerative colitis. *Alimentary pharmacology & therapeutics* 38, 151698 161 (2013).
- 69975.Maeda, Y., et al. Dysbiosis contributes to arthritis development via activation of autoreactive T700cells in the intestine. Arthritis & rheumatology 68, 2646-2661 (2016).
- 701 76. Pianta, A., *et al.* Evidence of the immune relevance of Prevotella copri, a gut microbe, in patients
 702 with rheumatoid arthritis. *Arthritis & rheumatology* 69, 964-975 (2017).
- 703 77. Glick-Bauer, M. & Yeh, M.-C. The health advantage of a vegan diet: exploring the gut microbiota
 704 connection. *Nutrients* 6, 4822-4838 (2014).
- 70578.Kovatcheva-Datchary, P., et al. Dietary fiber-induced improvement in glucose metabolism is706associated with increased abundance of Prevotella. Cell metabolism 22, 971-982 (2015).
- 707 79. Kim, D. & Kim, W.U. can Prevotella copri be a causative pathobiont in rheumatoid arthritis?
 708 *Arthritis & rheumatology* 68, 2565-2567 (2016).
- 70980.Wen, C., et al. Quantitative metagenomics reveals unique gut microbiome biomarkers in
ankylosing spondylitis. Genome biology 18, 142 (2017).
- 81. Ley, R.E. Gut microbiota in 2015: Prevotella in the gut: choose carefully. *Nature Reviews Gastroenterology & Hepatology* 13, 69-70 (2016).
- 82. Ebringer, R., Cooke, D., Cawdell, D.R., Cowling, P. & Ebringer, A. Ankylosing spondylitis: klebsiella
 and HL-A B27. *Rheumatology and rehabilitation* 16, 190-196 (1977).
- Stone, M., *et al.* Comparative immune responses to candidate arthritogenic bacteria do not
 confirm a dominant role for Klebsiella pneumonia in the pathogenesis of familial ankylosing
 spondylitis. *Rheumatology* 43, 148-155 (2003).
- 71884.Pugsley, A.P., Chapon, C. & Schwartz, M. Extracellular pullulanase of Klebsiella pneumoniae is a719lipoprotein. Journal of bacteriology 166, 1083-1088 (1986).

- 85. Ebringer, A. & Wilson, C. The use of a low starch diet in the treatment of patients suffering from
 ankylosing spondylitis. *Clinical rheumatology* **15**, 62-66 (1996).
- Rashid, T., Wilson, C. & Ebringer, A. The link between ankylosing spondylitis, Crohn's disease,
 Klebsiella, and starch consumption. *Clin Dev Immunol* **2013**, 872632 (2013).
- 724 87. Ciccia, F., *et al.* Dysbiosis and zonulin upregulation alter gut epithelial and vascular barriers in 725 patients with ankylosing spondylitis. *Ann Rheum Dis* **76**, 1123-1132 (2017).
- 72688.Kubinak, J.L., *et al.* MHC variation sculpts individualized microbial communities that control727susceptibility to enteric infection. *Nature communications* **6**, 8642 (2015).
- 728 89. Dubois, P.C., *et al.* Multiple common variants for celiac disease influencing immune gene 729 expression. *Nature genetics* **42**, 295-302 (2010).
- 73090.Brenner, O., et al. Loss of Runx3 function in leukocytes is associated with spontaneously731developed colitis and gastric mucosal hyperplasia. Proceedings of the National Academy of732Sciences of the United States of America 101, 16016-16021 (2004).




Figure 1: Taxonomic and functional dysbiosis observed in AS cases relative to healthy controls. **A.** Alpha and beta diversity analysis. sPLSDA and PERMANOVA revealed community-level differences in taxonomic composition. **B.** Commonly-differentiated bacterial species from the discovery and validation cohorts. **C.** Commonly-differentiated KEGG Orthogroups from the discovery and validation cohorts. Bacterial species and KEGG Orthogroups exhibiting significant results according to multivariate linear modelling and Wilcoxon rank-sum tests are shown.




Figure 2: Effect of TNFi therapy upon the microbiome. **A.** Alpha and beta diversity analysis. sPLSDA and PERMANOVA revealed community-level differences in taxonomic composition. **B.** Bacterial species modulated by the effects of TNFi treatment. Bacterial species exhibiting significant results according to multivariate linear modelling and Wilcoxon rank-sum tests are shown.




Figure 3: Effect of RUNX3 variants upon the microbiome. **A.** sPLSDA, alpha diversity and PERMANOVA community-level taxonomic analysis of the current study. **B.** sPSLDA, alpha diversity and PERMANOVA community-level taxonomic analysis of a recent 16S metabarcode study of healthy individuals. **C.** Modulated bacterial species according to significant results from multivariate linear modelling and Wilcoxon rank-sum testing. **D.** Modulated MetaCyc metabolic pathways, according to significant results from multivariate linear modelling and Wilcoxon rank-sum testing.




Figure 4: A. Enrichment, both in terms of abundance and diversity, of bacterial peptides homologous to HLA-B27 epitopes in AS cases relative to healthy controls. **B.** Differential abundance and diversity of bacterial peptides homologous to HLA-B27 epitopes in TNFi-treated and –untreated cases, and healthy controls.

Epitope ID	HLA-B27 subtype	Sequence
490238	B2702:B2704	ARFKSNVTKTMKGFEY
490238	B2702,B2704 B2704;B2705;B2709	MRLPAQLLGLLM
493505	B2704,B2705,B2709 B2702	NRHYTFYVW
493505	bioRxiv preprint doi: https://doi.org/10.1101/57143 certified by peer review) is the a	30; this version posted March 8, 2
491582	cerfifiéd4by peer review) is the a B2702	author/fundel?. AlPhonits teserved. QTTFLVDNKKVFGTHL
494083	B2702 B2702	RQIMTGFGELSY
434944	B2702;B2705;B2707;B2709	ARTPHWALF
492935	B2703	KRWESERVLSF
493023	B2705	LPVNLLLSTSGPF
492689	B2703;B2707;B2709	KRFDDKYTLKLT
492876	B2702	KRNEDEDSPNKLY
442808	B2702;B2703;B2708	ARLDIDPETITW
494092	B2702	RKFQPYKPFYY
495095	B2708	SRLEQGEEPWVL
490897	B2702	ERIATEFNQLQF
493564	B2702	NRQIVSGSRDKTIKLW
445935	B2702;B2703;B2707;B2708;B2709	KRNTFVGTPFWM
491482	B2702;B2703;B2704;B2705;B2706;B2707;B2708	GRFTIKSDVWSF
490741	B2702	ATTAALLLEAQAATGFLVDPVR
492710	B2703	KRFFFDVGSNKY
494342	B2707;B2709	RRIMRPTDVPDQGL
447192	B2702	QRGLWGGEGW
492970	B2702	KRYYDEVEAEGY
493651	B2702	QRAIQVDPNYAY
491073	B2702	FQWMSSRVSPNTLW
494077	B2705	QRYSLLPFWY

Table 1: Bacterial peptides homologous to HLA-B27-presented epitopes which were commonly enriched in the discovery and validation cohorts for AS cases.